Top

Published in:

01-10-2014 | Review

Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review

Authors: Hanan El Marroun, Tonya White, Frank C. Verhulst, Henning Tiemeier

Published in: European Child & Adolescent Psychiatry | Issue 10/2014

Abstract

Antidepressant and anxiolytic medications are widely prescribed and used by pregnant women for acute and maintenance therapy. These drugs are able to pass the placental barrier, and may potentially influence fetal and brain development. It is possible that exposure to prenatal antidepressants or anxiolytic medication may disturb neurotransmitter systems in the brain and have long-lasting consequences on neurodevelopment in the offspring. As all medication during pregnancy may pose a certain risk to the developing fetus, the potential benefits of the medication must be weighed against the risks for both mother and her unborn child. Therefore, information to guide patients and physicians to make a well-balanced decision for the appropriate treatment during pregnancy is needed. In this systematic review, an overview of maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes is provided. Some studies indicate a relation between prenatal exposure to antidepressants and adverse neurodevelopmental outcomes such as delayed motor development/motor control, social difficulties, internalizing problems and autism, but cannot rule out confounding by indication. Overall, the results of the observational studies have been inconsistent, which makes translation of the findings into clinical recommendations difficult. More well-designed observational studies and also randomized controlled trials (e.g., maintenance treatment vs. cessation) are needed to move forward and provide a comprehensive evaluation of the risks and benefits of antidepressant and anxiolytic use during pregnancy.

Available only for authorised users

Melville JL, Gavin A, Guo Y, Fan MY, Katon WJ (2010) Depressive disorders during pregnancy: prevalence and risk factors in a large urban sample. Obstet Gynecol 116:1064–1070PubMedPubMedCentral

Ross LE, McLean LM (2006) Anxiety disorders during pregnancy and the postpartum period: a systematic review. J Clin Psychiatry 67:1285–1298PubMed

Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS (2008) Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry 65:805–815PubMedPubMedCentral

Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR (2004) Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 103:698–709PubMed

O’Hara MW, Swain AM (1996) Rates and risk of postpartum depression—a meta-analysis. Int Rev Psychiatry 8:37–54

Zuckerman B, Amaro H, Bauchner H, Cabral H (1989) Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 160:1107–1111PubMed

Schetter CD (2011) Psychological science on pregnancy: stress processes, biopsychosocial models, and emerging research issues. Annu Rev Psychol 62:531–558

Goodman SH (2007) Depression in mothers. Annu Rev Clin Psychol 3:107–135PubMed

Goodman SH, Tully EC (2006) Depression in women who are mothers: an integrative model of risk for the development of psychopathology in their sons and daughters. In: Keyes CLM, Goodman SH (eds) Women and depression : a handbook for the social, behavioral, and biomedical sciences. Cambridge University Press, Cambridge, New York, pp 241–282

10.

Goodman SH, Gotlib IH (1999) Risk for psychopathology in the children of depressed mothers: a developmental model for understanding mechanisms of transmission. Psychol Rev 106:458–490PubMed

11.

Geddes J, Butler R, Hatcher S (2003) Depressive disorders. Clin Evid 9:1034–1057

12.

El Marroun H, Jaddoe VW, Hudziak JJ, Roza SJ, Steegers EA, Hofman A, Verhulst FC, White TJ, Stricker BH, Tiemeier H (2012) Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 69:706–714PubMed

13.

Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661PubMed

14.

Loughhead AM, Stowe ZN, Newport DJ, Ritchie JC, DeVane CL, Owens MJ (2006) Placental passage of tricyclic antidepressants. Biol Psychiatry 59:287–290PubMed

15.

van der Aa EM, Peereboom-Stegeman JH, Noordhoek J, Gribnau FW, Russel FG (1998) Mechanisms of drug transfer across the human placenta. Pharmac World Sci: PWS 20:139–148

16.

Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, Elliot R, Kok CH, Coenen A, Forman T (2009) Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 42:95–100PubMed

17.

Levitt P, Harvey JA, Friedman E, Simansky K, Murphy EH (1997) New evidence for neurotransmitter influences on brain development. Trends Neurosci 20:269–274PubMed

18.

Homberg JR, Schubert D, Gaspar P (2010) New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 31:60–65PubMed

19.

Olivier JD, Blom T, Arentsen T, Homberg JR (2011) The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review. Prog Neuropsychopharmacol Biol Psychiatry 35:1400–1408PubMed

20.

Haas M, Qu Z, Kim TH, Vargas E, Campbell K, Petrou S, Tan SS, Reid CA, Heng J (2013) Perturbations in cortical development and neuronal network excitability arising from prenatal exposure to benzodiazepines in mice. Eur J Neurosci 37:1584–1593PubMed

21.

Ross LE, Grigoriadis S, Mamisashvili L, Koren G, Steiner M, Dennis CL, Cheung A, Mousmanis P (2011) Quality assessment of observational studies in psychiatry: an example from perinatal psychiatric research. Int J Methods Psychiatr Res 20:224–234PubMed

22.

Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–384PubMedPubMedCentral

23.

Wells GA, Shea B, O’Connell D, Petersen K, Welch V, Losos M, Tugwell P (2003) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In: Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada

24.

Neal MJ (1997) Medical pharmacology at a glance. Blackwell Science, Oxford

25.

Cooper WO, Willy ME, Pont SJ, Ray WA (2007) Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196(544):e541–e545

26.

Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R (2008) Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198(194):e191–e195

27.

Alwan S, Reefhuis J, Rasmussen SA, Friedman JM (2011) Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 51:264–270PubMed

28.

Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT (2008) Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 65:600–606PubMedPubMedCentral

29.

Fenger-Gron J, Thomsen M, Andersen KS, Nielsen RG (2011) Paediatric outcomes following intrauterine exposure to serotonin reuptake inhibitors: a systematic review. Dan Med Bull 58:A4303PubMed

30.

Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C (2006) Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63:898–906PubMed

31.

Ververs T, Kaasenbrood H, Visser G, Schobben F, De Jong-Van Den Berg L, Egberts T (2006) Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 62:863–870PubMed

32.

Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nielsen RB, Norgaard M, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B (2012) Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 344:d8012PubMed

33.

Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, Yood MU, Morse AN, Platt R (2004) Prescription drug use in pregnancy. Am J Obstet Gynecol 191:398–407PubMed

34.

Daw JR, Mintzes B, Law MR, Hanley GE, Morgan SG (2012) Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001–2006). Clin Ther 34(239–249):e232

35.

Lacroix I, Hurault C, Sarramon MF, Guitard C, Berrebi A, Grau M, Albouy-Cossard C, Bourrel R, Elefant E, Montastruc JL, Damase-Michel C (2009) Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 65:839–846PubMed

36.

Lendoiro E, Gonzalez-Colmenero E, Concheiro-Guisan A, de Castro A, Cruz A, Lopez-Rivadulla M, Concheiro M (2013) Maternal hair analysis for the detection of illicit drugs, medicines, and alcohol exposure during pregnancy. Ther Drug Monit 35:296–304PubMed

37.

Marchetti F, Romero M, Bonati M, Tognoni G (1993) Use of psychotropic drugs during pregnancy. A report of the international co-operative drug use in pregnancy (DUP) study. Collaborative Group on Drug Use in Pregnancy (CGDUP). Eur J Clin Pharmacol 45:495–501PubMed

38.

Ornoy A, Arnon J, Shechtman S, Moerman L, Lukashova I (1998) Is benzodiazepine use during pregnancy really teratogenic? Reprod Toxicol 12:511–515PubMed

39.

Palmsten K, Hernandez-Diaz S, Huybrechts KF, Williams PL, Michels KB, Achtyes ED, Mogun H, Setoguchi S (2013) Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ 347:f4877PubMedPubMedCentral

40.

Gardarsdottir H, Heerdink ER, van Dijk L, Egberts AC (2007) Indications for antidepressant drug prescribing in general practice in the Netherlands. J Affect Disord 98:109–115PubMed

41.

Olkkola KT, Ahonen J (2008) Midazolam and other benzodiazepines. Handb Exp Pharmacol 182:335–360

42.

Sit DK, Perel JM, Helsel JC, Wisner KL (2008) Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 69:652–658PubMedPubMedCentral

43.

Little BB (1999) Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet Gynecol 93:858–868PubMed

44.

Whitaker-Azmitia PM, Druse M, Walker P, Lauder JM (1996) Serotonin as a developmental signal. Behav Brain Res 73:19–29PubMed

45.

Represa A, Ben-Ari Y (2005) Trophic actions of GABA on neuronal development. Trends Neurosci 28:278–283PubMed

46.

Lauder JM (1993) Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci 16:233–240PubMed

47.

Brummelte S, Galea LA, Devlin AM, Oberlander TF (2013) Antidepressant use during pregnancy and serotonin transporter genotype (SLC6A4) affect newborn serum reelin levels. Dev Psychobiol 55:518–529PubMed

48.

Bellissima V, Visser GH, Ververs TF, van Bel F, Termote JU, van der Heide M, Florio P, Volti GL, Gazzolo D (2011) Antenatal maternal antidepressants drugs affect Activin A concentrations in maternal blood, in amniotic fluid and in fetal cord blood. J Matern Fetal Neonatal Med 24(Suppl 2):31–34PubMed

49.

Laugesen K, Olsen MS, Andersen ABT, Froslev T, Sorensen HT (2013) In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder: a nationwide Danish cohort study. BMJ Open 3:e003507PubMedPubMedCentral

50.

Sorensen MJ, Gronborg TK, Christensen J, Parner ET, Vestergaard M, Schendel D, Pedersen LH (2013) Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol 5:449–459PubMedPubMedCentral

51.

El Marroun H, White TJ, van der Knaap NJF, Homberg JR, Fernandez G, Schoemaker NK, Jaddoe VW, Hofman A, Verhulst FC, Hudziak JJ, Stricker BH, Tiemeier H (Accepted for publication) Prenatal exposure to SSRIs and social responsiveness symptoms of autism: a population-based study of young children. Br J Psychiatry

52.

Pedersen LH, Henriksen TB, Bech BH, Licht RW, Kjaer D, Olsen J (2013) Prenatal antidepressant exposure and behavioral problems in early childhood—a cohort study. Acta Psychiatr Scand 127:126–135PubMed

53.

Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C (2013) Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ 346:f2059PubMedPubMedCentral

54.

Salisbury AL, Wisner KL, Pearlstein T, Battle CL, Stroud L, Lester BM (2011) Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment. Depress Anxiety 28:1008–1019PubMedPubMedCentral

55.

Suri R, Hellemann G, Stowe ZN, Cohen LS, Aquino A, Altshuler LL (2011) A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. J Clin Psychiatry 72:1002–1007PubMedPubMedCentral

56.

Warnock FF, Bakeman R, Shearer K, Misri S, Oberlander T (2009) Caregiving behavior and interactions of prenatally depressed mothers (antidepressant-treated and non-antidepressant-treated) during newborn acute pain. Infant Ment Health J 30:384–406

57.

Weikum WM, Oberlander TF, Hensch TK, Werker JF (2012) Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception. Proc Natl Acad Sci USA 109(Suppl 2):17221–17227PubMedPubMedCentral

58.

Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B (2012) Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry 169:1165–1174PubMed

59.

Pedersen LH, Henriksen TB, Olsen J (2010) Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 125:e600–e608PubMed

60.

Figueroa R (2010) Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J Dev Behav Pediatr: JDBP 31:641–648PubMed

61.

Kallen B (2004) Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 158:312–316PubMed

62.

Kallen B, Reis M (2012) Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. J Clin Psychopharmacol 32:608–614PubMed

63.

Laegreid L, Hagberg G, Lundberg A (1992) Neurodevelopment in late infancy after prenatal exposure to benzodiazepines—a prospective study. Neuropediatrics 23:60–67PubMed

64.

Mortensen JT, Olsen J, Larsen H, Bendsen J, Obel C, Sorensen HT (2003) Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Eur J Epidemiol 18:769–771PubMed

65.

Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G (2002) Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 159:1889–1895PubMed

66.

Gidai J, Acs N, Banhidy F, Czeizel AE (2008) An evaluation of data for 10 children born to mothers who attempted suicide by taking large doses of alprazolam during pregnancy. Toxicol Ind Health 24:53–60PubMed

67.

Gidai J, Acs N, Banhidy F, Czeizel AE (2008) A study of the effects of large doses of medazepam used for self-poisoning in 10 pregnant women on fetal development. Toxicol Ind Health 24:61–68PubMed

68.

Frisell T, Oberg S, Kuja-Halkola R, Sjolander A (2012) Sibling comparison designs: bias from non-shared confounders and measurement error. Epidemiology 23:713–720PubMed

69.

Batton B, Batton E, Weigler K, Aylward G, Batton D (2013) In utero antidepressant exposure and neurodevelopment in preterm infants. Am J Perinatol 30:297–301PubMed

70.

Austin MP, Karatas JC, Mishra P, Christl B, Kennedy D, Oei J (2013) Infant neurodevelopment following in utero exposure to antidepressant medication. Acta Paediatr, Int J Paediatr

71.

Misri S, Reebye P, Kendrick K, Carter D, Ryan D, Grunau RE, Oberlander TF (2006) Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 163:1026–1032PubMed

72.

Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JGW, Kulin N, Koren G (1997) Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258–262PubMed

73.

Boucher N, Bairam A, Beaulac-Baillargeon L (2008) A new look at the neonate’s clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol 28:334–339PubMed

74.

Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W (2005) Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 115:411–425PubMed

75.

Oberlander TF, Grunau RE, Fitzgerald C, Ellwood AL, Misri S, Rurak D, Riggs KW (2002) Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 51:443–453PubMed

76.

Smith MV, Sung A, Shah B, Mayes L, Klein DS, Yonkers KA (2013) Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors. Early Hum Dev 89:81–86PubMedPubMedCentral

77.

de Vries NKS, van der Veere CN, Reijneveld SA, Bos AF (2013) Early neurological outcome of young infants exposed to selective serotonin reuptake inhibitors during pregnancy: results from the observational SMOK study. PLoS One 8(5):e64654

78.

Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC (2011) Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology 217:211–219PubMed

79.

Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE (2003) Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 142:402–408PubMed

80.

Galbally M, Lewis AJ, Buist A (2011) Developmental outcomes of children exposed to antidepressants in pregnancy. Aust N Z J Psychiatry 45:393–399PubMed

81.

Klinger G, Frankenthal D, Merlob P, Diamond G, Sirota L, Levinson-Castiel R, Linder N, Stahl B, Inbar D (2011) Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol 31:615–620PubMed

82.

Oberlander TF, Papsdorf M, Brain UM, Misri S, Ross C, Grunau RE (2010) Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch Pediatr Adolesc Med 164:444–451PubMed

83.

Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V (2011) Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 68:1104–1112PubMed

84.

Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz-Picciotto I (2014) Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics [Epub ahead of print]

85.

Stika L, Elisova K, Honzakova L, Hrochova H, Plechatova H, Strnadova J, Skop B, Svihovec J, Vachova M, Vinar O (1990) Effects of drug administration in pregnancy on children’s school behaviour. Pharm Weekbl Sci 12:252–255PubMed

86.

Laegreid L, Hagberg G, Lundberg A (1992) The effect of benzodiazepines on the fetus and the newborn. Neuropediatrics 23:18–23PubMed

87.

Viggedal G, Hagberg BS, Laegreid L, Aronsson M (1993) Mental development in late infancy after prenatal exposure to benzodiazepines—a prospective study. J Child Psychol Psychiatry 34:295–305PubMed

88.

Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, National Birth Defects Prevention S (2007) Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684–2692PubMed

89.

Malm H, Artama M, Gissler M, Ritvanen A (2011) Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 118:111–120PubMed

90.

Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT (2010) First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 88:94–100PubMed

91.

Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354:579–587PubMed

92.

Lund N, Pedersen LH, Henriksen TB (2009) Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 163:949–954PubMed

93.

Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL (1996) Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335:1010–1015PubMed

94.

Klieger-Grossmann C, Weitzner B, Panchaud A, Pistelli A, Einarson T, Koren G, Einarson A (2012) Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study. J Clin Pharmacol 52:766–770PubMed

95.

Jensen HM, Gron R, Lidegaard O, Pedersen LH, Andersen PK, Kessing LV (2013) Maternal depression, antidepressant use in pregnancy and Apgar scores in infants. Br J Psychiatry: J Ment Sci 202:347–351

96.

Lim K, Sanders A, Brain U, Riggs W, Oberlander TF, Rurak D (2012) Third trimester fetal pulmonary artery Doppler blood flow velocity characteristics following prenatal selective serotonin reuptake inhibitor (SSRI) exposure. Early Hum Dev 88:609–615PubMed

97.

Nijenhuis CM, ter Horst PG, van Rein N, Wilffert B, de Jong-van den Berg LT (2012) Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2: testing the hypotheses. Br J Clin Pharmacol 73:126–134PubMedPubMedCentral

98.

Davidson S, Prokonov D, Taler M, Maayan R, Harell D, Gil-Ad I, Weizman A (2009) Effect of exposure to selective serotonin reuptake inhibitors. In Utero on fetal growth: potential role for the IGF-I and HPA axes. Pediatr Res 65:236–241PubMed

99.

Milkovich L, Van Den Berg BJ (1974) Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development. N Engl J Med 291:1268–1271PubMed

100.

Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR (1998) Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 317:839–843PubMedPubMedCentral

101.

Gidai J, Acs N, Banhidy F, Czeizel AE (2010) Congenital abnormalities in children of 43 pregnant women who attempted suicide with large doses of nitrazepam. Pharmacoepidemiol Drug Saf 19:175–182PubMed

102.

Calderon-Margalit R, Qiu C, Ornoy A, Siscovick DS, Williams MA (2009) Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol 201(579):e571–e578

103.

Czeizel AE, Szegal BA, Joffe JM, Racz J (1999) The effect of diazepam and promethazine treatment during pregnancy on the somatic development of human offspring. Neurotoxicol Teratol 21:157–167PubMed

104.

Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN (2006) Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295:499–507PubMed

105.

Verhamme K, Sturkenboom M (2011) Study designs in paediatric pharmacoepidemiology. Eur J Clin Pharmacol 67(Suppl 1):67–74PubMed

106.

Wisner KL, Zarin DA, Holmboe ES, Appelbaum PS, Gelenberg AJ, Leonard HL, Frank E (2000) Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 157:1933–1940PubMed

107.

Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W (2004) Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 65:230–237PubMed

108.

Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE (2007) Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 161:22–29PubMed

109.

Reebye PN, Ng TWC, Misri S, Stikarovska I (2012) Affect expression and self-regulation capacities of infants exposed in utero to psychotropics. Front Psychiatry 3

110.

Oberlander TF, Grunau R, Mayes L, Riggs W, Rurak D, Papsdorf M, Misri S, Weinberg J (2008) Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev 84:689–697PubMed

111.

Leibovitch L, Rymer-Haskel N, Schushan-Eisen I, Kuint J, Strauss T, Maayan-Metzger A (2013) Short-term neonatal outcome among term infants after in utero exposure to serotonin reuptake inhibitors. Neonatology 104:65–70PubMed

112.

Weikum WM, Mayes LC, Grunau RE, Brain U, Oberlander TF (2013) The impact of prenatal serotonin reuptake inhibitor (SRI) antidepressant exposure and maternal mood on mother-infant interactions at 3 months of age. Infant Behav Dev 36:485–493PubMed

113.

Weikum WM, Brain U, Chau CM, Grunau RE, Boyce WT, Diamond A, Oberlander TF (2013) Prenatal serotonin reuptake inhibitor (SRI) antidepressant exposure and serotonin transporter promoter genotype (SLC6A4) influence executive functions at 6 years of age. Front Cell Neurosci 7:180PubMedPubMedCentral

114.

Galbally M, Lewis A, Lum J, Buist A (2009) Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry 43:846–854PubMed

115.

Hale TW, Kendall-Tackett K, Cong Z, Votta R, McCurdy F (2010) Discontinuation syndrome in newborns whose mothers took antidepressants while pregnant or breastfeeding. Breastfeed Med 5:283–288PubMed

Title: Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review
Authors: Hanan El Marroun
Tonya White
Frank C. Verhulst
Henning Tiemeier
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: European Child & Adolescent Psychiatry / Issue 10/2014
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-014-0558-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2014

Antenatal depression and children’s developmental outcomes: potential mechanisms and treatment options

Does paternal mental health in pregnancy predict physically aggressive behavior in children?

Prenatal risk factors and postnatal central nervous system function

Identifying maternal risk factors associated with Fetal Alcohol Spectrum Disorders: a systematic review

Mechanisms underlying the effects of prenatal psychosocial stress on child outcomes: beyond the HPA axis

Maternal pre-pregnancy risk drinking and toddler behavior problems: the Norwegian Mother and Child Cohort Study